Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis

Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis

(2012) Fady Ibrahim et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

A novel mechanism for an old drug: Amphotericin B in the treatment of visceral leishmaniasis

(2011) Amitabha Chattopadhyay et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes

(2011) V. K. Prajapati et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

An Oral Formulation of Amphotericin B Attached to Functionalized Carbon Nanotubes Is an Effective Treatment for Experimental Visceral Leishmaniasis

(2011) Vijay Kumar Prajapati et al.   JOURNAL OF INFECTIOUS DISEASES

Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model

(2011) Olena Sivak et al.   Lipids in Health and Disease

Amphotericin B inhibits entry of Leishmania donovani into primary macrophages

(2010) Yamuna Devi Paila et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model

(2010) Ellen K. Wasan et al.   PLoS Neglected Tropical Diseases

Development and characterization of oral lipid-based Amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans

(2009) Ellen K. Wasan et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation

(2009) P. Gershkovich et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY